Tugba Bagci-Onder

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8926686/publications.pdf

Version: 2024-02-01

29	755	471371	552653
papers	citations	17	26
		h-index	g-index

33	33	33	1129
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Parameters Influencing Gene Delivery Efficiency of PEGylated Chitosan Nanoparticles: Experimental and Modeling Approach. Advanced NanoBiomed Research, 2022, 2, 2100033.	1.7	12
2	Tumor Cell Infiltration into the Brain in Glioblastoma: From Mechanisms to Clinical Perspectives. Cancers, 2022, 14, 443.	1.7	48
3	Genome-wide CRISPR screen identifies PRC2 and KMT2D-COMPASS as regulators of distinct EMT trajectories that contribute differentially to metastasis. Nature Cell Biology, 2022, 24, 554-564.	4.6	53
4	3D bioprinted glioma models. Progress in Biomedical Engineering, 2022, 4, 042001.	2.8	14
5	Chronically Radiation-Exposed Survivor Glioblastoma Cells Display Poor Response to Chk1 Inhibition under Hypoxia. International Journal of Molecular Sciences, 2022, 23, 7051.	1.8	3
6	Generation of TRAIL-resistant cell line models reveals distinct adaptive mechanisms for acquired resistance and re-sensitization. Oncogene, 2021, 40, 3201-3216.	2.6	5
7	Glioma-on-a-Chip Models. Micromachines, 2021, 12, 490.	1.4	19
8	Epigenetic Deregulation of Apoptosis in Cancers. Cancers, 2021, 13, 3210.	1.7	29
9	IDH Mutations in Glioma: Double-Edged Sword in Clinical Applications?. Biomedicines, 2021, 9, 799.	1.4	37
10	Systematic characterization of chromatin modifying enzymes identifies KDM3B as a critical regulator in castration resistant prostate cancer. Oncogene, 2020, 39, 2187-2201.	2.6	28
11	TRAIL-conjugated silver nanoparticles sensitize glioblastoma cells to TRAIL by regulating CHK1 in the DNA repair pathway. Neurological Research, 2020, 42, 1061-1069.	0.6	10
12	Drug Repositioning Screen on a New Primary Cell Line Identifies Potent Therapeutics for Glioblastoma. Frontiers in Neuroscience, 2020, 14, 578316.	1.4	1
13	Experimental data on novel Fe(III)-complexes containing phenanthroline derivatives for their anticancer properties. Data in Brief, 2019, 27, 104548.	0.5	2
14	May iron(III) complexes containing phenanthroline derivatives as ligands be prospective anticancer agents?. European Journal of Medicinal Chemistry, 2019, 176, 492-512.	2.6	35
15	The pro-apoptotic Bcl-2 family member Harakiri (HRK) induces cell death in glioblastoma multiforme. Cell Death Discovery, 2019, 5, 64.	2.0	26
16	Identification of SERPINE1 as a Regulator of Glioblastoma Cell Dispersal with Transcriptome Profiling. Cancers, 2019, 11, 1651.	1.7	43
17	The fungal metabolite chaetocin is a sensitizer for pro-apoptotic therapies in glioblastoma. Cell Death and Disease, 2019, 10, 894.	2.7	21
18	Stem Cells Engineered During Different Stages of Reprogramming Reveal Varying Therapeutic Efficacies. Stem Cells, 2018, 36, 932-942.	1.4	7

#	Article	IF	Citations
19	Gelatin Methacryloyl Hydrogels in the Absence of a Crosslinker as 3D Glioblastoma Multiforme (GBM)â€Mimetic Microenvironment. Macromolecular Bioscience, 2018, 18, 1700369.	2.1	43
20	A platinum blue complex exerts its cytotoxic activity via DNA damage and induces apoptosis in cancer cells. Chemical Biology and Drug Design, 2017, 90, 210-224.	1.5	3
21	Macromol. Biosci. 2/2017. Macromolecular Bioscience, 2017, 17, .	2.1	1
22	KDM2B, an H3K36-specific demethylase, regulates apoptotic response of GBM cells to TRAIL. Cell Death and Disease, 2017, 8, e2897-e2897.	2.7	26
23	Quinacrine Mediated Sensitization of Glioblastoma (GBM) Cells to TRAIL through MMP-Sensitive PEG Hydrogel Carriers. Macromolecular Bioscience, 2017, 17, 1600267.	2.1	28
24	Identification of Mitoxantrone as a TRAIL-sensitizing agent for Glioblastoma Multiforme. Cancer Biology and Therapy, 2016, 17, 546-557.	1.5	27
25	Targeting breast to brain metastatic tumours with death receptor ligand expressing therapeutic stem cells. Brain, 2015, 138, 1710-1721.	3.7	38
26	Derivation of Neural Stem Cells from Mouse Induced Pluripotent Stem Cells. Methods in Molecular Biology, 2015, 1357, 329-338.	0.4	3
27	Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 16642-16647.	3.3	70
28	Evaluating the Effect of Therapeutic Stem Cells on TRAIL Resistant and Sensitive Medulloblastomas. PLoS ONE, 2012, 7, e49219.	1.1	18
29	A Dual PI3K/mTOR Inhibitor, PI-103, Cooperates with Stem Cellâ€“Delivered TRAIL in Experimental Glioma Models. Cancer Research, 2011, 71, 154-163.	0.4	94